Clearside Biomedical, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CLSD Nasdaq 2834 clearsidebio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Clearside Biomedical, Inc.

Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore - Jan 22nd, 2025 12:05 pm
Clearside announces publication of insights on drug development, regulation - Dec 20th, 2024 12:16 pm
Analyst Sees 500% Upside for This Pharmaceutical Penny Stock - Dec 20th, 2024 10:29 am
Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye - Dec 19th, 2024 12:05 pm
Here's Why Clearside Biomedical (CLSD) Is a Great 'Buy the Bottom' Stock Now - Dec 12th, 2024 2:55 pm
Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States - Nov 25th, 2024 12:05 pm
All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy - Nov 15th, 2024 5:00 pm
Clearside Biomedical Third Quarter 2024 Earnings: Beats Expectations - Nov 15th, 2024 11:43 am
Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Call Highlights: Promising Clinical Trial ... - Nov 13th, 2024 7:17 am
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue Estimates - Nov 12th, 2024 11:05 pm
Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Nov 12th, 2024 9:05 pm
Even after rising 13% this past week, Clearside Biomedical (NASDAQ:CLSD) shareholders are still down 77% over the past three years - Nov 10th, 2024 12:40 pm
Santen, Arctic Vision sign deal for ARVN001 to treat UME - Nov 8th, 2024 8:56 am
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema - Nov 7th, 2024 2:05 pm
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference - Nov 6th, 2024 12:05 pm
Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors - Nov 4th, 2024 12:05 pm
Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024 - Oct 31st, 2024 11:05 am
Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting - Oct 22nd, 2024 11:05 am
Morning Movers: Arcadium Lithium surges after deal to be acquired - Oct 10th, 2024 12:57 pm
Clearside Biomedical's Investigational Drug For Vision Loss Hits Primary Goals In Mid-Stage Study - Oct 9th, 2024 2:22 pm